Synergy IMT creates therapeutics with the potential to treat a broad range of cancer and non-cancer diseases. 

Recent milestones have culminated in multiple filed and to be filed patents. These cover new cancer targets and groundbreaking drug candidates.

SYN120 is a bispecific T cell engaging antibody that targets a solid tumor antigen identified at Synergy IMT.  The novel tumor antigen that is selected for direct elimination of tumor cells and inhibition of tumorigenic and metastatic mechanisms. 

SYN220 is a antibody drug conjugate (ADC) that targets an antigen identified at synergy IMT that is broadly expressed on different tumor types including colon, gastric, pancreatic and breast.

SYN320  is a multivalent molecule designed to modify pathogenic processes in cancer and non-cancer diseases.